Noven Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of prescription transdermal products and transdermal drug delivery technologies. It operates through two segments, Noven Transdermals and Noven Therapeutics. The Noven Transdermals segmentÂ’s products include Daytrana, a transdermal patch for the treatment of attention deficit hyperactivity disorder; Vivelle-Dot, a prescribed transdermal estrogen therapy product in the United States, as well as marketed primarily under the Estradot brand name outside the United States; CombiPatch, a combination estrogen/progestin transdermal patch marketed under the Estalis brand name outside the United States; Amphetamine Patch, a phase 1 clinical trial product for attention deficit hyperactivity disorder; and HSDD Patch for hypoactive sexual desire disorders. The Noven Therapeutics segmentÂ’s products comprise Pexeva for depressive disorder, panic disorder, obsessive compulsive disorder, and generalized anxiety disorder; Lithobid for bipolar disorder and related manic episodes; Stavzor for bipolar disorder, migraine therapy, and epilepsy; Stavzor ER, a pre-clinical trial product for bipolar disorder, migraine therapy, and epilepsy; Lithium QD for bipolar disorder and related manic episodes; Mesafem for vasomotor symptoms; and DentiPatch for dental pain associated with certain dental procedures. Noven Pharmaceuticals markets its products in the United States, Canada, and Japan, as well as in Europe. It has collaboration with Procter & Gamble Pharmaceuticals, Inc. for the development of new prescription patches for hypoactive sexual desire disorder. The company was founded in 1987 and is headquartered in Miami, Florida.
$8.09 (03/02/09)
